Amyloidosis – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of amyloidosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of amyloidosis for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 10 years for the major mature pharmaceutical markets of the United States, Europe, and Japan.

Clarivate Epidemiology’s amyloidosis forecast will answer the following questions:

• Of all people diagnosed with amyloidosis, how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends such as population aging and improving life expectancy affect the epidemiology of amyloidosis over the forecast period?
• How will the increasing uptake of tafamidis for ATTR-CM impact the epidemiology of this condition over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following amyloidosis patient populations:

• Diagnosed incident cases of amyloidosis.
• Diagnosed prevalent cases of amyloidosis.
• Diagnosed incident cases of amyloid light chain (AL) amyloidosis.
• Diagnosed prevalent cases of AL amyloidosis.
• Diagnosed incident cases of amyloid A (AA) amyloidosis.
• Diagnosed prevalent cases of AA amyloidosis.
• Diagnosed incident cases of ATTR-CM.
• Diagnosed prevalent cases of ATTR-CM.
• Diagnosed incident cases of ATTR-FAP.
• Diagnosed prevalent cases of ATTR-FAP.
• Diagnosed prevalent cases of drug-treated amyloidosis.

Note: Coverage may vary by country.